ALGLUCOSIDASE ALFA (MYOZYME)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II
Conditions
Glycogen Storage Disease Type II
Trial Timeline
Dec 4, 2018 → Dec 30, 2020
NCT ID
NCT03687333About ALGLUCOSIDASE ALFA (MYOZYME)
ALGLUCOSIDASE ALFA (MYOZYME) is a approved stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is completed. This product is registered under clinical trial identifier NCT03687333. Target conditions include Glycogen Storage Disease Type II.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03687333 | Approved | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II